MN/CA IX and EGFR pathway inhibition
View Patent ↗The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with the p85 subunit of PI3K to activate Akt, which in turn is associated with anti-apototic function and increased cell survival. The latter finding indicates that there is a positive feedback loop for CA9 expression mediated by the PI3K pathway in preneoplastic/neoplastic diseases. Disclosed herein are novel therapeutic methods for treating preneoplastic/neoplastic diseases associated with abnormal MN/CA IX expression, using EGFR pathway inhibitors. Preferably, the EGFR pathway inhibitors are tyrosine kinase inhibitors or EGFR-specific antibodies. Further disclosed are methods for patient therapy selection for EGFR pathway inhibitors, preferably in combination with other cancer therapies, based on detection of abnormal MN/CA9 gene expression in preneoplastic/neoplastic tissues.
1. A method of inhibiting EGF receptor dependent signaling on the phosphorylation of carbonic anhydrase 9 (MN/CA IX) in a human subject with renal cell carcinoma, wherein said disease is characterized by abnormal MN/CA9 gene expression, comprising:
(a) obtaining a sample of body fluid or preneoplastic/neoplastic tissue from said human;
(b) detecting and quantifying the level of MN/CA9 gene expression product in said sample; and
(c) if said MN/CA9 gene expression product level in said sample is increased as compared to normal control, administering to said human a therapeutically effective amount of a composition comprising an EGFR tyrosine kinase inhibitor
wherein said tyrosine kinase inhibitor inhibits EGFR dependent phosphorylation of MN/CA IX.
2. The method of claim 1 , wherein said tyrosine kinase inhibitor is selected from the group consisting of gefitinib, erlotinib, lapatinib, canertinib, and EKB-569.
3. The method of claim 1 , wherein said EGFR tyrosine kinase inhibitor is conjugated to an antibody or a binding fragment thereof which specifically binds MN/CA IX.
4. The method of claim 1 further comprising administering to said human radiation and/or a therapeutically effective amount in a physiologically acceptable formulation of one or more of the following compounds selected from the group consisting of: conventional anticancer drug, chemotherapeutic agent, Sorafenib (BAY 43-9006), an omega-carboxypyridyl substituted urea, MN/CA IX-specific antibody or a binding fragment thereof.